Ranking  |  Company (Ticker)  |  Potential Upside
1 Progress Software Corporation (NASDAQ:PRGS) 984.0%
2 Media General, Inc. (NYSE:MEG) 493.7%
3 Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) 347.8%
4 MELA Sciences, Inc. (NASDAQ:MELA) 317.5%
5 Cytokinetics, Inc. (NASDAQ:CYTK) 311.2%
6 Celldex Therapeutics, Inc. (NASDAQ:CLDX) 269.6%
7 Peregrine Pharmaceuticals (NASDAQ:PPHM) 241.5%
8 The Princeton Review, Inc (NASDAQ:REVU) 240.1%
9 Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) 222.2%
10 AVANIR Pharmaceuticals (NASDAQ:AVNR) 215.8%
11 Neostem Inc. (AMEX:NBS) 214.7%
12 LECG Corporation (NASDAQ:XPRT) 209.2%
13 Enzo Biochem, Inc. (NYSE:ENZ) 205.0%
14 NeurogesX, Inc (NASDAQ:NGSX) 194.1%
15 Microvision, Inc. (NASDAQ:MVIS) 177.8%
16 Novavax, Inc. (NASDAQ:NVAX) 168.7%
17 Rodman & Renshaw Capital Group Inc. (NASDAQ:RODM) 166.7%
18 Vical Incorporated (NASDAQ:VICL) 164.6%
19 American Apparel Inc. (AMEX:APP) 163.2%
20 CytRx Corporation (NASDAQ:CYTR) 158.0%
21 PURE Bioscience (NASDAQ:PURE) 155.5%
22 Zogenix, Inc. (NASDAQ:ZGNX) 148.0%
23 Ligand Pharmaceuticals Inc. (NASDAQ:LGND) 148.0%
24 BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) 145.2%
25 Inhibitex, Inc. (NASDAQ:INHX) 135.0%
26 Broadwind Energy Inc. (NASDAQ:BWEN) 132.2%
27 MannKind Corporation (NASDAQ:MNKD) 127.8%
28 L&L Energy, Inc. (NASDAQ:LLEN) 127.0%
29 Inovio Pharmaceuticals, Inc. (AMEX:INO) 125.2%
30 Nymox Pharmaceutical Corporation (NASDAQ:NYMX) 120.0%
31 Dyax Corp. (NASDAQ:DYAX) 118.0%
32 Omeros Corporation (NASDAQ:OMER) 117.2%
33 Pharmacyclics, Inc. (NASDAQ:PCYC) 115.6%
34 Allos Therapeutics, Inc. (NASDAQ:ALTH) 115.2%
35 Keryx Biopharmaceuticals (NASDAQ:KERX) 112.3%
36 CKX Inc. (NASDAQ:CKXE) 110.0%
37 FuelCell Energy, Inc. (NASDAQ:FCEL) 108.3%
38 Array BioPharma Inc. (NASDAQ:ARRY) 106.6%
39 Value Line, Inc. (NASDAQ:VALU) 106.5%
40 Local.com Corp. (NASDAQ:LOCM) 105.4%
41 Geron Corporation (NASDAQ:GERN) 102.4%
42 Cenveo, Inc. (NYSE:CVO) 102.1%
43 Neuralstem, Inc. (AMEX:CUR) 102.0%
44 Rochester Medical Corporation (NASDAQ:ROCM) 100.1%
45 Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) 99.1%
46 EXACT Sciences Corporation (NASDAQ:EXAS) 97.3%
47 Dynavax Technologies Corporation (NASDAQ:DVAX) 94.8%
48 Cornerstone Therapeutics, Inc. (NASDAQ:CRTX) 93.4%
49 Aoxing Pharmaceutical Company, Inc. (AMEX:AXN) 91.4%
50 Biodel Inc (NASDAQ:BIOD) 91.3%

Tags: Alexza Pharmaceuticals, Allos Therapeutics, American Apparel Inc., Aoxing Pharmaceutical Company, Array BioPharma Inc., AVANIR Pharmaceuticals, Biodel Inc, BioSante Pharmaceuticals, Broadwind Energy Inc., Celldex Therapeutics, Cenveo, Chelsea Therapeutics International Ltd., CKX Inc., Cornerstone Therapeutics, Cytokinetics, CytRx Corporation, Dyax Corp., Dynavax Technologies Corporation, Enzo Biochem, EXACT Sciences Corporation, FuelCell Energy, Geron Corporation, Inc., Inhibitex, Inovio Pharmaceuticals, Keryx Biopharmaceuticals, L&L Energy, LECG Corporation, Ligand Pharmaceuticals Inc., Local.com Corp., MannKind Corporation, Media General, MELA Sciences, Microvision, Neostem Inc., Neuralstem, NeurogesX, Novavax, Nymox Pharmaceutical Corporation, Omeros Corporation, Peregrine Pharmaceuticals, Pharmacyclics, Progress Software Corporation, PURE Bioscience, Rochester Medical Corporation, Rodman & Renshaw Capital Group Inc., Somaxon Pharmaceuticals, The Princeton Review, Value Line, Vical Incorporated, Zogenix

This entry was posted on Thursday, February 24th, 2011 at 11:01 pm and is filed under Asset Management, Best Lists, Equity Capital Markets, Investing, Investment Ideas, Region: North America, Sales & Trading. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.